Empros Pharma

Privately held: no public share price · Sweden

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
GI lipase + intestinal alpha-glucosidaseSmall molecule
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 November 2025Topline resultOrlistat/acarbose (EMP16)Phase 2 POEM study of EMP16 (NCT06993428): positive topline results

Financial reports

No financial reports recorded.